Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood City, California.
| Revenue (TTM) | $1.28B |
| Gross Profit (TTM) | $833.70M |
| EBITDA | $-464.36M |
| Operating Margin | -36.80% |
| Return on Equity | -4584.00% |
| Return on Assets | -19.90% |
| Revenue/Share (TTM) | $9.70 |
| Book Value | $-2.05 |
| Price-to-Book | 55.67 |
| Price-to-Sales (TTM) | 15.83 |
| EV/Revenue | 17.93 |
| EV/EBITDA | -5.40 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.10% |
| Shares Outstanding | $134.20M |
| Float | $129.98M |
| % Insiders | 3.98% |
| % Institutions | 102.05% |
Volatility is currently expanding
Evaluate the expected performance of Guardant Health (GH) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and current Executive Chairman of the Dexcom board, with decades of strategic leadership experience in digital health technology. “We are excited to welcome Kevin Sayer to Guardant's board,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “Kevin has played a piv.
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential upside toward $250 if buyers defend key breakout support.
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider's America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research companies in the category. The inaugural Business Insider list recognizes companies for their innovative performance over the preceding five years, positioning Guardant am.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. “We strongly disagree with this decision and will prompt.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GH and any ticker you trade — then tracks every position and per-strategy win rate.
